{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:13Z","timestamp":1793068453152,"version":"4.5.0"},"reference-count":285,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cluster of Excellence Precision Medicine in Chronic Inflammation","award":["DFG EXC 2167"],"award-info":[{"award-number":["DFG EXC 2167"]}]},{"name":"Cluster of Excellence Precision Medicine in Chronic Inflammation","award":["CS01-2022"],"award-info":[{"award-number":["CS01-2022"]}]},{"name":"Clinician Scientist School L\u00fcbeck","award":["DFG EXC 2167"],"award-info":[{"award-number":["DFG EXC 2167"]}]},{"name":"Clinician Scientist School L\u00fcbeck","award":["CS01-2022"],"award-info":[{"award-number":["CS01-2022"]}]},{"name":"Schleswig-Holstein Excellence-Chair Program from the State of Schleswig-Holstein","award":["DFG EXC 2167"],"award-info":[{"award-number":["DFG EXC 2167"]}]},{"name":"Schleswig-Holstein Excellence-Chair Program from the State of Schleswig-Holstein","award":["CS01-2022"],"award-info":[{"award-number":["CS01-2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed\/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.<\/jats:p>","DOI":"10.3390\/biom13040634","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:32:28Z","timestamp":1680262348000},"page":"634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Dupilumab in Inflammatory Skin Diseases: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-7148","authenticated-orcid":false,"given":"Henning","family":"Olbrich","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-048X","authenticated-orcid":false,"given":"Christian D.","family":"Sadik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"},{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"},{"name":"Institute and Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, 23566 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-4886","authenticated-orcid":false,"given":"Katharina","family":"Boch","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, 23566 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e15120","DOI":"10.1111\/dth.15120","article-title":"Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jdcr.2019.03.016","article-title":"Recalcitrant prurigo nodularis treated successfully with dupilumab","volume":"5","author":"Rambhia","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhai, L.L., Savage, K.T., Qiu, C.C., Jin, A., Valdes-Rodriguez, R., and Mollanazar, N.K. (2019). Chronic Pruritus Responding to Dupilumab\u2014A Case Series. Medicines, 6.","DOI":"10.3390\/medicines6030072"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1111\/jdv.15584","article-title":"Dramatic improvement of generalized prurigo nodularis with dupilumab","volume":"33","author":"Calugareanu","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2340\/00015555-3243","article-title":"Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review","volume":"99","author":"Almustafa","year":"2019","journal-title":"Acta Derm.-Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab Treatment for Generalized Prurigo Nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_12","first-page":"940","article-title":"Dupilumab Treatment for Prurigo Nodularis and Pruritis","volume":"18","author":"Tanis","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamadermatol.2018.3906","article-title":"Reduced Itch Associated with Dupilumab Treatment In 4 Patients with Prurigo Nodularis","volume":"155","author":"Mollanazar","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_14","first-page":"e8737","article-title":"Resolution of Treatment-Refractory Prurigo Nodularis with Dupilumab: A Case Series","volume":"12","author":"Wieser","year":"2020","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/jdv.15957","article-title":"Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients","volume":"34","author":"Calugareanu","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/DER.0000000000000517","article-title":"Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis","volume":"31","author":"Napolitano","year":"2020","journal-title":"Dermatitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ddg.14107","article-title":"Dupilumab for treatment-refractory prurigo nodularis","volume":"18","author":"Rose","year":"2020","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1111\/ijd.14994","article-title":"Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis","volume":"59","author":"Criado","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13201","DOI":"10.1111\/dth.13201","article-title":"Efficacy of dupilumab in prurigo nodularis in elderly patient","volume":"33","author":"Giura","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.25251\/skin.4.3.13","article-title":"Treatment of Recalcitrant Prurigo Nodularis with Dupilumab","volume":"4","author":"Reynolds","year":"2020","journal-title":"Ski. J. Cutan. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13222","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: Case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","article-title":"Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo","volume":"83","author":"Chiricozzi","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdcr.2021.10.005","article-title":"Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab","volume":"18","author":"Bloomstein","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaad.2021.02.038","article-title":"Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study","volume":"85","author":"Georgakopoulos","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/09546634.2019.1659479","article-title":"Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: Our experience of efficacy","volume":"32","author":"Ferrucci","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/JAA.S300975","article-title":"Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy","volume":"14","author":"Liu","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.18176\/jiaci.0550","article-title":"Safety and Effectiveness of Dupilumab in Prurigo Nodularis","volume":"31","author":"Romano","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1111\/jdv.17046","article-title":"Our experience with prurigo nodularis treated with dupilumab","volume":"35","author":"Tilotta","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00105-020-04721-0","article-title":"Erfolgreiche Behandlung einer chronischen Prurigo mit Dupilumab","volume":"72","author":"Winkler","year":"2020","journal-title":"Der Hautarzt"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2147\/CCID.S379231","article-title":"Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series","volume":"15","author":"Luo","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"adv00754","DOI":"10.2340\/actadv.v102.2151","article-title":"Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series","volume":"102","author":"Lundqvist","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.abd.2022.01.011","article-title":"Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis","volume":"98","author":"Mitsuyama","year":"2022","journal-title":"An. Bras. Dermatol."},{"key":"ref_33","unstructured":"Gade, A., Ghani, H., and Rubenstein, R. (2022, December 06). Dupilumab, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585114\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40257-021-00646-z","article-title":"Dupilumab Facial Redness\/Dupilumab Facial Dermatitis: A Guide for Clinicians","volume":"23","author":"Muzumdar","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis\u2014A systematic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_36","first-page":"S1545961619P1053X","article-title":"Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis","volume":"18","author":"Maloney","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e15924","DOI":"10.1111\/dth.15924","article-title":"Dupilumab: Advances in the off-label usage of IL4 \/ IL13 antagonist in dermatoses","volume":"35","author":"Jia","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_39","unstructured":"OCEBM Levels of Evidence Working Group (2023, March 28). \u2018The Oxford Levels of Evidence 2\u2019. Oxford Centre for Evidence-Based Medicine. Available online: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e13290","DOI":"10.1111\/dth.13290","article-title":"Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults","volume":"33","author":"Patruno","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaad.2019.12.054","article-title":"Dupilumab treatment of nummular dermatitis: A retrospective cohort study","volume":"82","author":"Choi","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2018.07.043","article-title":"Dupilumab use in allergic contact dermatitis","volume":"80","author":"Machler","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.36849\/JDD.6246","article-title":"Chromate-Induced Allergic Contact Dermatitis Treated with Dupilumab","volume":"20","author":"Wilson","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/ajd.13740","article-title":"Treatment of generalised isobornyl acrylate contact allergy from diabetes pump with Dupilumab","volume":"63","author":"Arasu","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cod.13545","article-title":"Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones","volume":"83","author":"Ruge","year":"2020","journal-title":"Contact Dermat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jdcr.2019.01.023","article-title":"Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab","volume":"5","author":"Zhu","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1111\/dth.12701","article-title":"A case series of dupilumab-treated allergic contact dermatitis patients","volume":"31","author":"Goldminz","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1159\/000524380","article-title":"Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series","volume":"238","author":"Slodownik","year":"2022","journal-title":"Dermatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/DER.0000000000000409","article-title":"Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis","volume":"29","author":"Joshi","year":"2018","journal-title":"Dermatitis\u00ae"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/cod.13134","article-title":"Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab","volume":"80","year":"2019","journal-title":"Contact Dermat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/DER.0000000000000414","article-title":"Dupilumab as a Treatment for Allergic Contact Dermatitis","volume":"29","author":"Chipalkatti","year":"2018","journal-title":"Dermatitis\u00ae"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2018.12.048","article-title":"A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis","volume":"80","author":"Chipalkatti","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/DER.0000000000000446","article-title":"Dupilumab for Systemic Allergy Syndrome with Dermatitis","volume":"30","author":"Jacob","year":"2019","journal-title":"Dermatitis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaad.2019.03.020","article-title":"Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis","volume":"81","author":"Stout","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1111\/jocd.15112","article-title":"Successfully treatment with Dupilumab for systemic contact dermatitis following hair dye in a patient with dermatomyositis","volume":"21","author":"Jin","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cod.14238","article-title":"Contact sensitivity to sesquiterpene lactone mix and artichoke in a patient with severe recurrent dermatitis: A puzzling case","volume":"88","author":"Gallo","year":"2023","journal-title":"Contact Dermat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1111\/jdv.18099","article-title":"Dupilumab for the treatment of refractory allergic contact dermatitis from rubber\/latex concomitant with atopic dermatitis","volume":"36","author":"Koh","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/occmed\/kqaa152","article-title":"Mixed occupational and iatrogenic allergic contact dermatitis in a hairdresser","volume":"70","author":"Hamann","year":"2020","journal-title":"Occup. Med."},{"key":"ref_61","first-page":"1","article-title":"Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control","volume":"1","author":"Mainville","year":"2023","journal-title":"Contact Dermat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaad.2021.02.044","article-title":"Effect of dupilumab on allergic contact dermatitis and patch testing","volume":"84","author":"Jo","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaad.2019.12.053","article-title":"Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients","volume":"82","author":"Waldman","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","first-page":"1165","article-title":"Successful treatment of recalcitrant dyshidrotic eczema with dupilumab in a child","volume":"17","author":"Weins","year":"2019","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_65","first-page":"e557","article-title":"Treatment of chronic hand eczema with dupilumab\u2014A retrospective follow-up study","volume":"37","author":"Olesen","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cod.14104","article-title":"The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis\u201452 week results from the Dutch BioDay Registry","volume":"87","author":"Voorberg","year":"2022","journal-title":"Contact Dermat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/cod.13693","article-title":"Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab","volume":"84","author":"Loman","year":"2021","journal-title":"Contact Dermat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jdcr.2020.02.010","article-title":"Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report","volume":"6","author":"Zhu","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cod.13501","article-title":"Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab","volume":"83","author":"Halling","year":"2020","journal-title":"Contact Dermat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/1346-8138.14982","article-title":"Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study","volume":"46","author":"Oosterhaven","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000496481","article-title":"A Retrospective Review of Dupilumab for Hand Dermatitis","volume":"235","author":"Lee","year":"2019","journal-title":"Dermatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamadermatol.2018.2027","article-title":"Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema","volume":"154","author":"Oosterhaven","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2018.02.073","article-title":"Dupilumab for hand eczema","volume":"79","author":"Zirwas","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","first-page":"355","article-title":"Dupilumab in the Treatment of Dyshidrosis: A Report of Two Cases","volume":"17","author":"Weston","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_75","first-page":"211","article-title":"A Case of Complete Resolution of Severe Plantar Dyshidrotic Eczema With Dupilumab","volume":"18","author":"Nanda","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S399340","article-title":"Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review","volume":"16","author":"Li","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_77","first-page":"558","article-title":"Two Cases of Recalcitrant Dyshidrotic Eczema Treated with Dupilumab","volume":"20","author":"Peters","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_78","first-page":"484","article-title":"Occupational Chronic Hand Dermatitis in Hospital Environment Successfully Treated with Dupilumab: A Case Report","volume":"21","author":"Gan","year":"2022","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e15839","DOI":"10.1111\/dth.15839","article-title":"Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jdcr.2021.03.006","article-title":"Eczematous reactions to psoriasis biologics treated with dupilumab: A case series","volume":"11","author":"Koschitzky","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaad.2020.07.023","article-title":"The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging","volume":"83","author":"Shahriari","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Brummer, G.C., Wang, L.T., and Sontheimer, R.D. (2018). A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol. Online J., 24.","DOI":"10.5070\/D3242038109"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1684\/ejd.2020.3954","article-title":"Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency","volume":"31","author":"Votquenne","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_84","first-page":"e7831","article-title":"Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis","volume":"12","author":"Schrom","year":"2020","journal-title":"Cureus"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/pde.14464","article-title":"Dupilumab for pediatric prurigo nodularis: A case report","volume":"38","author":"Fachler","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2020.3947","article-title":"Dupilumab treatment of prurigo nodularis in an adolescent","volume":"31","author":"Giovannini","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdcr.2021.10.030","article-title":"Six cases of refractory pruritus and histologic dermal hypersensitivity reaction successfully treated with dupilumab","volume":"19","author":"Edmonds","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/09546634.2021.1880542","article-title":"Treatment of patients with chronic pruritus of unknown origin with dupilumab","volume":"33","author":"Jeon","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/bjd.18852","article-title":"Dupilumab as a treatment for generalized idiopathic pruritus: A report of two cases","volume":"182","author":"Stanger","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jdcr.2019.01.024","article-title":"A successful case of dupilumab treatment for severe uremic pruritus","volume":"5","author":"Silverberg","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e15296","DOI":"10.1111\/dth.15296","article-title":"Dupilumab treatment for cholestatic pruritus","volume":"35","author":"Chovatiya","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2021.02.005","article-title":"The use of dupilumab for the treatment of recalcitrant brachioradial pruritus","volume":"10","author":"Abel","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijwd.2018.08.010","article-title":"Recalcitrant anal and genital pruritus treated with dupilumab","volume":"4","author":"Yang","year":"2018","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e15926","DOI":"10.1111\/dth.15926","article-title":"Treatment of acquired reactive perforating collagenosis with dupilumab in a patient with end-stage renal disease","volume":"35","author":"Lee","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e15916","DOI":"10.1111\/dth.15916","article-title":"Reactive perforating collagenosis treated with dupilumab: A case report and literature review","volume":"35","author":"Guo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2022.08.013","article-title":"Dupilumab in acquired perforating dermatosis: A potential new treatment","volume":"28","author":"Alsebayel","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ajd.13874","article-title":"Reactive perforating collagenosis successfully treated with dupilumab","volume":"63","author":"Loughlin","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1002\/iid3.574","article-title":"Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD","volume":"10","author":"Ying","year":"2022","journal-title":"Immunity Inflamm. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity","volume":"153","author":"Huebner","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_105","first-page":"e263","article-title":"Dupilumab as a novel therapy for bullous pemphigoid","volume":"62","author":"Zhang","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_106","first-page":"e144","article-title":"Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: Two case reports","volume":"62","author":"Xu","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e15541","DOI":"10.1111\/dth.15541","article-title":"Case report: Dupilumab for the treatment of bullous pemphigoid","volume":"35","author":"Wang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1684\/ejd.2021.4190","article-title":"Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: A case series of three patients","volume":"31","author":"Liu","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e15330","DOI":"10.1111\/dth.15330","article-title":"A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab","volume":"35","author":"Shan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.09.014","article-title":"Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab","volume":"17","author":"Bal","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ajd.13692","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Saleh, M., Reedy, M., Torok, H., and Weaver, J. (2021). Successful treatment of bullous pemphigoid with dupilumab: A case and brief review of the literature. Dermatol. Online J., 27.","DOI":"10.5070\/D3274053155"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"611549","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid","volume":"11","author":"Jafari","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Seidman, J.S., Eichenfield, D.Z., and Orme, C.M. (2019). Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol. Online J., 25.","DOI":"10.5070\/D32511046147"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/1027-8117.357999","article-title":"Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy","volume":"40","author":"Tseng","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdcr.2022.09.017","article-title":"Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient","volume":"29","author":"Zhou","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e15243","DOI":"10.1111\/dth.15243","article-title":"The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab","volume":"35","author":"Li","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_120","first-page":"e30541","article-title":"The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab","volume":"14","author":"Savoldy","year":"2022","journal-title":"Cureus"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e15623","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Klepper, E.M., and Robinson, H.N. (2021). Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: A case report and review of the literature. Dermatol. Online J., 27.","DOI":"10.5070\/D327955136"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Khazaeli, M., Grover, R., and Pei, S. (2023). Concomitant nivolumab associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma. J. Cutan. Pathol.","DOI":"10.1111\/cup.14383"},{"key":"ref_125","first-page":"e135","article-title":"Severe bullous pemphigoid following COVID-19 vaccination resistant to rituximab and successfully treated with dupilumab","volume":"37","author":"Baffa","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e15648","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_127","first-page":"4144","article-title":"Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/ced.14765","article-title":"Treatment of pemphigoid gestationis with dupilumab","volume":"46","author":"Loughlin","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3389\/fmed.2022.1023458","article-title":"Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab","volume":"9","author":"Li","year":"2022","journal-title":"Front. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jdcr.2022.11.011","article-title":"Lichen planus pemphigoides successfully treated with dupilumab","volume":"31","author":"Song","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdcr.2021.02.010","article-title":"Successful treatment of Brunsting-Perry pemphigoid with dupilumab","volume":"10","author":"Blum","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_132","first-page":"1113","article-title":"Successful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab","volume":"20","author":"Raef","year":"2021","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e15727","DOI":"10.1111\/dth.15727","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e15890","DOI":"10.1111\/dth.15890","article-title":"A severe case of IgA bullous pemphigoid successfully treated with dupilumab","volume":"35","author":"Valenti","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jdcr.2022.10.035","article-title":"Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris","volume":"31","author":"Moore","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_137","first-page":"234","article-title":"A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated with Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/bjd.18855","article-title":"Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab","volume":"182","author":"Shehadeh","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/pde.14493","article-title":"Epidermolysis bullosa pruriginosa treated with dupilumab","volume":"38","author":"Bs","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2021.07.036","article-title":"Epidermolysis bullosa pruriginosa responding to dupilumab","volume":"16","author":"Clawson","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e15130","DOI":"10.1111\/dth.15130","article-title":"Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report","volume":"34","author":"Wang","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1111\/jdv.17887","article-title":"A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab","volume":"36","author":"Caroppo","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/ijd.16322","article-title":"A case of Hailey-Hailey disease successfully treated with dupilumab","volume":"61","author":"Licata","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_145","first-page":"e776","article-title":"Dupilumab in Hailey-Hailey disease: A case series","volume":"36","author":"Loughlin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjd.20475","article-title":"Hailey\u2013Hailey disease treated with dupilumab: A case series","volume":"185","author":"Alzahrani","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdcr.2022.01.029","article-title":"Can\u2019t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: Prompt resolution with dupilumab","volume":"22","author":"Shelton","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamadermatol.2020.5097","article-title":"Treatment of Grover Disease with Dupilumab","volume":"157","author":"Butler","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e15429","DOI":"10.1111\/dth.15429","article-title":"A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective?","volume":"35","author":"Barei","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_152","first-page":"9359","article-title":"Improvement of atopic dermatitis and alopecia universalis with dupilumab: A case report","volume":"14","author":"Alotaibi","year":"2022","journal-title":"Dermatol. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000517832","article-title":"Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe Atopic Dermatitis","volume":"8","author":"Romagnuolo","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ccr3.2915","article-title":"Effectiveness of Dupilumab in the treatment of both atopic dermatitis and alopecia universalis","volume":"8","author":"Call","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.18176\/jiaci.0541","article-title":"Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis with Dupilumab","volume":"31","author":"Szekely","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e13582","DOI":"10.1111\/dth.13582","article-title":"Rapid hair regrowth induced by dupilumab in a patient affected by alopecia totalis of 28 years\u2019 duration: Clinical and dermoscopic features","volume":"33","author":"Babino","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.alit.2020.02.009","article-title":"Dupilumab therapy rapidly improved alopecia areata associated with trichotillomania in an atopic dermatitis patient","volume":"69","author":"Ushida","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjd.18976","article-title":"The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: A case series of seven patients","volume":"183","author":"Harada","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_159","first-page":"1278","article-title":"Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients","volume":"17","author":"Ludriksone","year":"2019","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_160","first-page":"e223","article-title":"Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature","volume":"61","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2340\/00015555-3183","article-title":"Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report","volume":"99","author":"Uchida","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdcr.2018.11.007","article-title":"Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab","volume":"5","author":"Smogorzewski","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_163","first-page":"534","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e13023","DOI":"10.1111\/dth.13023","article-title":"Dupilumab and alopecia: A Janus effect","volume":"32","author":"Patruno","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdcr.2018.11.006","article-title":"Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis","volume":"5","author":"Alniemi","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e15255","DOI":"10.1111\/dth.15255","article-title":"Dupilumab-induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review","volume":"35","author":"Flanagan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/1346-8138.15631","article-title":"Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: A Japanese case report","volume":"48","author":"Muto","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/jdv.15571","article-title":"Hair regrowth and dissemination of molluscum contagiosum: Two unexpected effects with dupilumab","volume":"33","author":"Sevray","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.12788\/cutis.0659","article-title":"Visconti Dupilumab as a Therapeutic Approach in Alopecia Universalis","volume":"110","author":"Visconti","year":"2022","journal-title":"Cutis"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cia2.12289","article-title":"Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review","volume":"6","author":"Fukuyama","year":"2023","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdcr.2021.07.025","article-title":"Time to loss of response for dupilumab in ophiasis-pattern alopecia areata","volume":"15","author":"Choe","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jdcr.2022.09.015","article-title":"Dupilumab, incontinentia pigmenti, and alopecia: A serendipitous observation","volume":"29","author":"Zilberstein","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e936488","DOI":"10.12659\/AJCR.936488","article-title":"Long-Term Efficacy of Dupilumab in Alopecia Areata","volume":"23","author":"Kulkarni","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2021.07.015","article-title":"Dupilumab for the treatment of alopecia areata in children with atopic dermatitis","volume":"16","author":"Cho","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2021.01.046","article-title":"Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis","volume":"84","author":"McKenzie","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jdcr.2020.10.010","article-title":"Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab","volume":"6","author":"Gruenstein","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamadermatol.2018.2976","article-title":"Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab","volume":"154","author":"Penzi","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1111\/jdv.18029","article-title":"Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab","volume":"36","author":"Napolitano","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Bares","year":"2022","journal-title":"Allergy"},{"key":"ref_180","first-page":"e612","article-title":"Alopecia areata development in atopic dermatitis patients treated with dupilumab","volume":"34","author":"Trense","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cyto.2015.05.019","article-title":"Mast cell production and response to IL-4 and IL-13","volume":"75","author":"McLeod","year":"2015","journal-title":"Cytokine"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/ALX02382E","article-title":"Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab","volume":"7","author":"Puxkandl","year":"2023","journal-title":"Allergol. Sel."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/kjm2.12531","article-title":"Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab","volume":"38","author":"Sun","year":"2022","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/ijd.16009","article-title":"Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis","volume":"61","author":"Holm","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e14821","DOI":"10.1111\/dth.14821","article-title":"Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review","volume":"34","author":"Errichetti","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2050313X221117702","DOI":"10.1177\/2050313X221117702","article-title":"Long-term follow-up of patients treated with dupilumab for chronic spontaneous urticaria: A case report","volume":"10","author":"Abadeh","year":"2022","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2020.1782326","article-title":"Severe chronic spontaneous urticaria in children\u2014Treatment options according to the guidelines and beyond\u2014A 10 years review","volume":"33","author":"Staubach","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jdcr.2022.12.009","article-title":"Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab","volume":"32","author":"Zhu","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"AB312","DOI":"10.1016\/j.jaci.2021.12.002","article-title":"Dupilumab Significantly Reduces Itch and Hives in Patients with Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)","volume":"149","author":"Maurer","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.anai.2022.08.538","article-title":"DUPILUMAB EFFICACY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA BY IGE LEVEL: LIBERTY-CSU CUPID STUDY A","volume":"129","author":"Maurer","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ced.14081","article-title":"Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment","volume":"45","author":"Ferrucci","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CCID.S343462","article-title":"Cholinergic Urticaria, an Effective and Safe \u201cOff Label\u201d Use of Dupilumab: A Case Report with Literature Review","volume":"15","author":"Sirufo","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.anai.2020.06.034","article-title":"Dupilumab as a novel therapy to treat adrenergic urticaria","volume":"126","author":"Goodman","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1054422","DOI":"10.3389\/fimmu.2022.1054422","article-title":"Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_196","first-page":"1636","article-title":"Treatment of Netherton syndrome with dupilumab","volume":"20","author":"Odorici","year":"2022","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e15862","DOI":"10.1111\/dth.15862","article-title":"A Netherton syndrome case report: Response to dupilumab treatment","volume":"35","author":"Galdo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000525987","article-title":"Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series","volume":"239","author":"Ragamin","year":"2022","journal-title":"Dermatology"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Inaba, Y., Kanazawa, N., Muraoka, K., Yariyama, A., Kawaguchi, A., Kunimoto, K., Kaminaka, C., Yamamoto, Y., Tsujioka, K., and Yoshida, A. (2022). Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study. Children, 9.","DOI":"10.3390\/children9030310"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/1346-8138.16253","article-title":"Successful treatment of Netherton syndrome with dupilumab: A case report and review of the literature","volume":"49","author":"Wang","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jdermsci.2021.03.003","article-title":"Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome","volume":"102","author":"Murase","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/pde.14362","article-title":"Netherton syndrome: Temporary response to dupilumab","volume":"37","author":"Aktas","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_203","first-page":"e152","article-title":"Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling","volume":"35","author":"Traupe","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/ced.14317","article-title":"Successful treatment with dupilumab of an adult with Netherton syndrome","volume":"45","author":"Andreasen","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of Netherton Syndrome With Dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/BTT.S362391","article-title":"Successful Treatment of an Adult with Atopic Dermatitis and Lamellar Ichthyosis Using Dupilumab","volume":"16","author":"Binkhonain","year":"2022","journal-title":"Biol. Targets Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/ski2.87","article-title":"Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab","volume":"2","author":"Steinhoff","year":"2022","journal-title":"Ski. Health Dis."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10875-021-01194-1","article-title":"Peeling Skin Syndrome Type 1: Dupilumab Reduces IgE, But Not Skin Anomalies","volume":"42","author":"Alexis","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/ced.14642","article-title":"Successful treatment of trichothiodystrophy with dupilumab","volume":"46","author":"Gruber","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.abd.2020.10.006","article-title":"Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis","volume":"96","author":"Chello","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdcr.2020.12.004","article-title":"Refractory pruritus responds to dupilumab in a patient with TTC7A mutation","volume":"8","author":"Tehrany","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/pde.14717","article-title":"Generalized eczematous dermatitis and pruritus responsive to dupilumab in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome","volume":"38","author":"Maher","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anai.2022.06.020","article-title":"Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia","volume":"129","author":"Atwal","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jdcr.2020.02.030","article-title":"Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment","volume":"6","author":"Wieser","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2022.03.017","article-title":"Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome","volume":"29","author":"Du","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jdcr.2019.07.026","article-title":"Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia","volume":"5","author":"Jin","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e13725","DOI":"10.1111\/dth.13725","article-title":"Targeted inhibition of IL -4\/13 with dupilumab is an effective treatment for eosinophilic dermatosis of hematologic malignancy","volume":"33","author":"Goyal","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1111\/jdv.17232","article-title":"Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy","volume":"35","author":"Maglie","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s10875-020-00751-4","article-title":"Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome","volume":"40","author":"Barbieux","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/pde.15072","article-title":"Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab","volume":"39","author":"Nihal","year":"2022","journal-title":"Pediatr. Dermatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e13770","DOI":"10.1111\/pai.13770","article-title":"Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome","volume":"33","author":"Viglizzo","year":"2022","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_224","first-page":"e367","article-title":"Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome","volume":"36","author":"Wang","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_225","first-page":"e15237","article-title":"Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy","volume":"35","author":"Cortina","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"e2021050351","DOI":"10.1542\/peds.2021-050351","article-title":"Dupilumab for STAT3-Hyper-IgE Syndrome with Refractory Intestinal Complication","volume":"148","author":"Lu","year":"2021","journal-title":"Pediatrics"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1016\/j.jaip.2021.06.049","article-title":"Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome","volume":"9","author":"Dixit","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdcr.2021.03.007","article-title":"Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis","volume":"11","author":"Su","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"108452","DOI":"10.1016\/j.clim.2020.108452","article-title":"Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome","volume":"215","author":"Sogkas","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"646997","DOI":"10.3389\/fped.2021.646997","article-title":"Case Report: Dupilumab Successfully Controls Severe Eczema in a Child with Elevated IgE Levels and Recurrent Skin Infections","volume":"9","author":"Joshi","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/1346-8138.15955","article-title":"Treatment options for DOCK8 deficiency-related severe dermatitis","volume":"48","author":"Ollech","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamadermatol.2021.5885","article-title":"Treatment of Kimura Disease with Dupilumab","volume":"158","author":"Teraki","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/SAP.0000000000003106","article-title":"Kimura Disease of the Thigh Treated with Surgical Excision and Dupilumab","volume":"88","author":"Huang","year":"2022","journal-title":"Ann. Plast. Surg."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e15674","DOI":"10.1111\/dth.15674","article-title":"Dupilumab for recalcitrant Kimura disease","volume":"35","author":"Bellinato","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1084879","DOI":"10.3389\/fimmu.2022.1084879","article-title":"Successful treatment of dupilumab in Kimura disease independent of IgE: A case report with literature review","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamadermatol.2019.0946","article-title":"Use of Dupilumab in the Treatment of Papuloerythroderma of Ofuji","volume":"155","author":"Teraki","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_237","first-page":"e739","article-title":"Rapid effects of dupilumab treatment on papuloerythroderma of Ofuji","volume":"34","author":"Nonoyama","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000524716","article-title":"A Case of Papuloerythroderma Successfully Treated with Dupilumab","volume":"14","author":"Mizuno","year":"2022","journal-title":"Case Rep. Dermatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/ddg.14598","article-title":"Dupilumab in eosinophilic cellulitis (Wells\u2019 syndrome)\u2014Case report of a potential new treatment option","volume":"19","author":"Traidl","year":"2021","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Kirven, R.M., and Plotner, A.N. (2022). Wells syndrome successfully treated with dupilumab. Int. J. Dermatol., 36349453.","DOI":"10.1111\/ijd.16501"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1111\/pde.13533","article-title":"Eosinophilic annular erythema treated with dupilumab","volume":"35","author":"Gordon","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_242","first-page":"1031","article-title":"Refractory eosinophilic annular erythema treated successfully with dupilumab","volume":"18","author":"Maione","year":"2020","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1111\/ced.15379","article-title":"Dupilumab for treatment of eosinophilic fasciitis","volume":"47","author":"Xia","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jamadermatol.2022.1969","article-title":"Use of Dupilumab and Eosinophil Targeted Therapy in Treating Angiolymphoid Hyperplasia with Eosinophilia","volume":"158","author":"Franke","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jdcr.2022.03.002","article-title":"Treatment of lichen sclerosus and hypertrophic scars with dupilumab","volume":"23","author":"Peterson","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_246","first-page":"e28270","article-title":"Dupilumab Failure in Treating Dermatomyositis-Associated Pruritus","volume":"14","author":"Hsu","year":"2022","journal-title":"Cureus"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid-sparing treatment for IgG4-related disease","volume":"79","author":"Simpson","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/jdv.16097","article-title":"Keloid lesions show increased IL -4\/ IL -13 signaling and respond to Th2-targeting dupilumab therapy","volume":"34","author":"Diaz","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jdcr.2021.04.034","article-title":"Dupilumab as an adjuvant treatment for keloid-associated symptoms","volume":"13","author":"Wong","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/jdv.17669","article-title":"Lack of efficacy of dupilumab in the treatment of keloid disorder","volume":"36","author":"Tirgan","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"197","DOI":"10.36849\/JDD.6252","article-title":"Nonresponse and Progression of Diffuse Keloids to Dupilumab Therapy","volume":"21","author":"Luk","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jdcr.2019.05.006","article-title":"Dupilumab for the treatment of severe photodermatitis","volume":"5","author":"Smith","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/phpp.12566","article-title":"Dupilumab for the treatment of chronic actinic dermatitis","volume":"36","author":"Patel","year":"2020","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/CCID.S342401","article-title":"Successful Treatment of Chronic Actinic Dermatitis with Dupilumab: A Case Report and Review of the Literature","volume":"14","author":"Chen","year":"2021","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/phpp.12731","article-title":"Chronic actinic dermatitis in an old adult significantly improved by dupilumab","volume":"38","author":"Chen","year":"2022","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/phpp.12851","article-title":"Chronic actinic dermatitis successfully treated with methotrexate and dupilumab","volume":"39","author":"McFeely","year":"2023","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"803692","DOI":"10.3389\/fmed.2022.803692","article-title":"Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series","volume":"9","author":"Ali","year":"2022","journal-title":"Front. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2050313X19845235","DOI":"10.1177\/2050313X19845235","article-title":"A case report of therapeutically challenging chronic actinic dermatitis","volume":"7","author":"Verma","year":"2019","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/pde.14311","article-title":"Clearance of pediatric actinic prurigo with dupilumab","volume":"37","author":"Eickstaedt","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pde.15146","article-title":"Atopic dermatitis-like graft-versus-host disease treated with dupilumab","volume":"40","author":"Larijani","year":"2022","journal-title":"Pediatr. Dermatol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e15781","DOI":"10.1111\/dth.15781","article-title":"Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report","volume":"35","author":"Zheng","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jdcr.2022.10.019","article-title":"Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab","volume":"30","author":"Kazemi","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_263","first-page":"E8","article-title":"Dupilumab for the Treatment of Lichen Planus","volume":"107","author":"Pousti","year":"2021","journal-title":"Cutis"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/ced.15387","article-title":"Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab","volume":"47","author":"Cho","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e15645","DOI":"10.1111\/dth.15645","article-title":"Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa","volume":"35","author":"Molinelli","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/jdv.16280","article-title":"A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab","volume":"34","author":"Gambardella","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2020.10.021","article-title":"Recalcitrant generalized granuloma annulare treated successfully with dupilumab","volume":"7","author":"Song","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"e15005","DOI":"10.1111\/dth.15005","article-title":"A case of lichen amyloidosis associated with atopic dermatitis successfully treated with dupilumab: A case report and literature review","volume":"34","author":"Aoki","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1111\/jdv.18482","article-title":"Dramatic response to dupilumab in papular amyloidosis","volume":"36","author":"Zahid","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"0513030","DOI":"10.5070\/D32612051364","article-title":"Clinical resolution of generalized lichen amyloidosis with dupilumab: A new alternative therapy","volume":"26","author":"Humeda","year":"2020","journal-title":"Dermatol. Online J."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaip.2018.07.027","article-title":"Dupilumab for treatment of food allergy","volume":"7","author":"Rial","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell Lymphoma and Concomitant Atopic Dermatitis Responding to Dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"adv00271","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e13880","DOI":"10.1111\/dth.13880","article-title":"Progression of mycosis fungoides after treatment with dupilumab: A case report","volume":"33","author":"Miyashiro","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1111\/1346-8138.15501","article-title":"Dupilumab therapy in S\u00e9zary syndrome misdiagnosed as atopic dermatitis: A case report","volume":"47","author":"Umemoto","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"adv00766","DOI":"10.2340\/actadv.v102.2234","article-title":"Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression","volume":"102","author":"Hashimoto","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm.-Venereol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/dermatopathology9040045","article-title":"Dupilumab-Associated Mycosis Fungoides with a CD8+ Immunophenotype","volume":"9","author":"Park","year":"2022","journal-title":"Dermatopathology"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Newsom, M., Hrin, M.L., Hamid, R.N., Strowd, L.C., Ahn, C., Jorizzo, J.L., and Feldman, S.R. (2021). Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol. Online J., 27.","DOI":"10.5070\/D3271052041"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Tran, J., Morris, L., Vu, A., and Duvic, M. (2020). Development of S\u00e9zary syndrome following the administration of dupilumab. Dermatol. Online J., 26.","DOI":"10.5070\/D3264048364"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamadermatol.2022.0613","article-title":"Treatment with Dupilumab for Refractory Cutaneous B-Cell Pseudolymphoma","volume":"158","author":"Joshi","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","article-title":"Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash","volume":"14","author":"Trum","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1080\/09546634.2022.2102121","article-title":"Dupilumab for the treatment of adult atopic dermatitis in special populations","volume":"33","author":"Patruno","year":"2022","journal-title":"J. Dermatol. Treat."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/4\/634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:07:28Z","timestamp":1760123248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/4\/634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":285,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["biom13040634"],"URL":"https:\/\/doi.org\/10.3390\/biom13040634","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}